Allison M. Green

Allison M. Green

Auto-generated profile, based on publicly available information

Allison M. Green

The University of Texas at Austin

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2022 in Nano Letters
Verified
Journal Article
Open access
AGAllison M. Green
Allison M. Green
COCharles K. Ofosu
Charles K. Ofosu
JKJiho Kang
Jiho Kang
EAEric Anslyn
Eric Anslyn
TTThomas M. Truskett
Thomas M. Truskett
DMDelia J. Milliron
Delia J. Milliron
Inorganic nanocrystal gels retain distinct properties of individual nanocrystals while offering tunable, network-structure-dependent characteristics. We review different mechanisms for assembling gels from colloidal nanocrystals including (1) controlled destabilization, (2) direct bridging, (3) depletion, as well as linking mediated by (4) coordination bonding or (5) dynamic covalent bonding, and we highlight how each impacts gel properties. These approaches use nanocrystal surface chemistry or the addition of small molecules to mediate inter-nanocrystal attractions. Each method offers advantages in terms of gel stability, reversibility, or tunability and presents new opportunities for the design of reconfigurable materials and fueled assemblies.

20 December 2023 in ACS Nano
Verified
Journal Article
Closed access
WCWoo Je Chang
Woo Je Chang
ZSZarko Sakotic
Zarko Sakotic
AWAlexander Ware
Alexander Ware
AGAllison M. Green
Allison M. Green
BRBenjamin J. Roman
Benjamin J. Roman
DMDelia J. Milliron
Delia J. Milliron

22 February 2024 in ACS Photonics
Verified
Journal Article
Closed access
AGAllison M. Green
Allison M. Green
WCWoo Je Chang
Woo Je Chang
ZSZachary M. Sherman
Zachary M. Sherman
ZSZarko Sakotic
Zarko Sakotic
KKKihoon Kim
Kihoon Kim
TTThomas M. Truskett
Thomas M. Truskett


14 October 2021 in Journal of Child and Adolescent Psychopharmacology
Verified
Journal Article
Open access
JLJames Luccarelli
James Luccarelli
TMThomas H. McCoy
Thomas H. McCoy
MUMai Uchida
Mai Uchida
AGAllison Green
Allison Green
SSStephen J. Seiner
Stephen J. Seiner
MHMichael E. Henry
Michael E. Henry
Objective: Electroconvulsive therapy (ECT) is the most effective acute treatment for depression, but its use in younger patients is rare and heavily regulated in many U.S. states. It is unclear whether age modifies treatment response or tolerability in adolescents, transitional age youth, and young adults. We examined the effects of ECT on depression and cognition in patients aged 16–30 years. Methods: A retrospective cohort study of patients aged 16–30 years receiving ECT between 2011 and 2020 who were evaluated with the Quick Inventory of Depressive Symptomatology (QIDS), the Behavior and Symptom Identification Scale-24 (BASIS-24), and the Montreal Cognitive Assessment (MoCA) at baseline and following treatment #10. Results: Among the 424 patients who met the inclusion criteria, ECT was associated with a decrease in depression symptoms (ΔQIDS −6.7; Kruskal–Wallis rank sum test; χ 2 = 293.37; df = 2; p < 0.0001) and improvement in overall self-reported mental health status (ΔBASIS-24 − 0.70; Kruskal–Wallis rank sum test; χ 2 = 258.5; df = 2; p < 0.0001) during the first 10 treatments, with a slight reduction in cognition as measured by the MoCA (ΔMoCA −1.1; Kruskal–Wallis rank sum test; χ 2 = 33.7; df = 1; p < 0.0001). Age was not a significant predictor of QIDS, BASIS-24, or MoCA changes. Conclusions: Among 424 patients aged 16–30 years receiving acute course ECT, age was not a significant predictor of improvement in depression, change in overall self-reported mental health status, or change in cognition. These results support the utility of ECT in the treatment of adolescents and young adults.

27 February 2021 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
JBJoseph Biederman
Joseph Biederman
MDMaura DiSalvo
Maura DiSalvo
AGAllison Ba Green
Allison Ba Green
KWK. Yvonne Ba Woodworth
K. Yvonne Ba Woodworth
CLCecilia Ba Law
Cecilia Ba Law
SFStephen V. V Faraone
Stephen V. V Faraone
Purpose/Background: This study aimed to evaluate the frequency of needing to switch the initial treatment of a stimulant to the alternative family in newly referred, medication-naive adults with attention-deficit/hyperactivity disorder (ADHD) initiating treatment with stimulants. Methods/Procedures: Subjects were 49 unmedicated adults (18–45 years old) with Diagnostic and Statistical Manual of Disorders (Fifth Edition) ADHD who initiated treatment with a stimulant. Before the clinical assessment with an expert clinician, participants completed the Adult Self-Report, Behavior Rating Inventory of Executive Function—Adult Version, Emotional Dysregulation Subscale of the Barkley Current Behavior Scale—Self-report, and Mind Wandering Questionnaire. The rate of switching was examined using information from the electronic medical record for up to three clinical follow-up visits. Comparisons were made between those who did and did not need to switch on baseline demographic and clinical characteristics. Findings/Results: Sixty-seven percent of ADHD patients were initially prescribed a methylphenidate product, and 33%, an amphetamine product. Forty-one percent of ADHD patients needed to switch from their initially prescribed stimulant family within 90 days of initiating treatment because of poor tolerability. Whereas the rate of switching was significantly higher in those initially prescribed methylphenidate, the rate of patients who required changes in formulation (long- to short-acting and vice versa) or additional antianxiety or antidepressant treatment (“strugglers”) was higher in those taking amphetamine. Switchers were more impaired on the Adult Self-Report Intrusive scale, whereas nonswitchers were more impaired on the Behavior Rating Inventory of Executive Function Inhibit and Task Monitor scales. However, these findings were small and of unclear clinical significance. Implications/Conclusions: Forty-one percent of medication-naive adults with ADHD initiating stimulant treatment required a switch from the initially prescribed stimulant family to the alternative one because of poor tolerability. Switching could not be adequately predicted by baseline demographic or clinical characteristics. These findings call for improved efforts to help identify predictors of response to stimulant treatment in adults with ADHD to avoid unnecessary delays in identifying a safe and effective treatment for these patients.